King Tari A, DeCensi Andrea
Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
Division of Medical Oncology, Department of Medicine, E.O. Ospedali Galliera, Genoa, Italy.
Cancer Prev Res (Phila). 2024 Dec 3;17(12):545-547. doi: 10.1158/1940-6207.CAPR-24-0483.
The uptake and adherence of preventive therapy of breast cancer in clinical practice are low because of fear of serious adverse events and menopausal symptoms. Low-dose tamoxifen has been shown to retain efficacy while reducing toxicity in high-risk women. In this issue of the journal, Cornell and colleagues evaluated uptake, adherence, and tolerability of low-dose tamoxifen in high-risk women. More than 70% of patients reported that they took low-dose tamoxifen after counseling and were still taking the medication at 1 year. This paradigm shift may move the field of breast cancer prevention forward and reduce breast cancer incidence and mortality. See related article by Cornell et al., p. 565.
由于担心严重不良事件和更年期症状，乳腺癌预防性治疗在临床实践中的接受度和依从性较低。低剂量他莫昔芬已被证明在高危女性中可在降低毒性的同时保持疗效。在本期杂志中，康奈尔及其同事评估了高危女性对低剂量他莫昔芬的接受度、依从性和耐受性。超过70%的患者报告称，他们在接受咨询后服用了低剂量他莫昔芬，并且在1年后仍在服用该药物。这种模式转变可能会推动乳腺癌预防领域的发展，并降低乳腺癌的发病率和死亡率。见康奈尔等人的相关文章，第565页。
